Carnevale Carmela

Endothelial Cell Density After XEN Implant Surgery: Short-term Data From the Italian XEN Glaucoma Treatment Registry (XEN-GTR).

The mean ECD reduction 6 months after XEN implantation was low. The ECD reduction in the XEN+phaco group was larger than in the XEN-solo group but was similar to that observed in the phaco-solo group.

Regional Vessel Density Reduction in the Macula and Optic Nerve Head of Patients With Pre-Perimetric Primary Open Angle Glaucoma.

In ppOAG patients, VD biomarkers in both the macula and ONH, alongside RNFL, GCC, and macular thickness, were significantly reduced before detectable visual field loss with regional specificity.

Vascular Density and Retinal Structure Relationships Across Sectors and Regions of the Optic Nerve in Patients With Primary Open Angle Glaucoma.

Early-stage POAG patients have a stronger relationship between RPC VD and RNFL in the temporal regions of the ONH compared with non-glaucomatous controls, with the TS sector demonstrating the largest difference between groups.

Spatial Summation in the Glaucomatous Macula: A Link With Retinal Ganglion Cell Damage.

Macular sensitivity loss in glaucoma is better described by a model in which RA changes with RGC loss. Structural measurements have limited dynamic range.

Exploring the relationship between accommodation and intraocular pressure: a systematic literature review and meta-analysis.

Accommodation has an impact on IOP measurements and, overall, determines IOP decrease in healthy individuals.

Correction: Managing the ocular surface after glaucoma filtration surgery: an orphan topic.

Managing the ocular surface after glaucoma filtration surgery: an orphan topic.

Clinicians are encouraged to routinely include the OS evaluation after GFS and to consider proper management when the occurrence of PGS-OSD worsen the patient's QOL or exert negative effects to the FB functionality.

Effectiveness and safety of XEN45 implant over 12 months of follow-up: data from the XEN-Glaucoma Treatment Registry.

Over 1-year follow-up, XEN45 alone or in combination with phacoemulsification, had comparable success rates and effectively and safely lowered IOP and the need for OHM.